A new race has been initiated between biosimilar and branded drug manufacturers to gain maximum revenue share from insulin market. The upcoming three years are very crucial for insulin manufacturers, as most of the branded insulin are going to be off patent which would results into the loss of around US$53 Bn revenue for branded manufacturers in 2016. Generic manufacturers are expected to take smaller chunk of this amount owing to their local presence which would restrain them take share ... Read more

Insulin biosimilars are bioidentical or highly similar versions of original, or brand name, insulin medicines. These biosimilars can treat conditions like Diabetes Mellitus by maintaining blood glucose levels within defined ranges. Unlike generic drugs which are identical copies of original drugs, biosimilars are derived from living cells and are more complex to replicate. However, they have been clinically proven to be as safe and effective as the reference biologic medicines they are ... Read more